ReviewDiscover oncology2025
Omics-enhanced nanomedicine: integrating multi-omics for precision cancer diagnosis and therapy.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer nanomedicine has emerged as a transformative approach in oncology, providing targeted therapeutic strategies with enhanced efficacy and reduced systemic toxicity. The integration of multi-omics technologies has further revolutionized this field.This review was conducted based on a systematic literature search using PubMed, Web of Science, and Scopus databases. Keywords included “cancer nanomedicine,” “multi-omics,” “precision oncology,” “nanoparticle,” and related terms. The search was limited to articles published between 2000 and 2024. Only English-language full-text articles reporting original research or clinical studies relevant to omics-enhanced nanomedicine were included. This review uniquely synthesizes recent advances in omics-enhanced nanomedicine, highlighting the integration of multi-omics data for precision cancer therapy. Key innovations include omics-driven nanoparticle design, patient stratification via biomarker panels, and synergy with immunotherapy. Future directions focus on AI-aided data integration and clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.